Post-hoc analysis evaluating safety of atogepant in ADVANCE & open-label extension participants with cardiovascular risk factors

被引：0
|
作者：
Blumenfeld, A. M. [1 ,2 ]
Pavlovic, J. M. [3 ]
Harriott, A. [4 ]
Best, P. J. [5 ]
Monteith, T. [6 ]
Ferreira, R. [7 ]
Ma, J. [7 ]
Smith, J. H. [7 ]
Dabruzzo, B. L. [7 ,8 ]
Nahas, S. J. [9 ]
机构：
[1] Headache Ctr Southern Calif, Carlsbad, CA USA
[2] Headache Ctr Southern Calif, San Diego, CA USA
[3] Albert Einstein Coll Med, Montefiore Headache Ctr, Bronx, NY 10467 USA
[4] Massachusetts Gen Hosp, Boston, MA 02114 USA
[5] Mayo Clin, Rochester, MN USA
[6] Univ Miami, Miami, FL USA
[7] AbbVie Inc, Madison, NJ USA
[8] AbbVie Inc, Frederick, MD USA
[9] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
来源：
HEADACHE | 2022年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-137
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [31] Efficacy and Tolerability of Solifenacin in Patients Aged ≥ 65 Years with Overactive Bladder: Post-Hoc Analysis of 2 Open-Label Studies
    Capo', James P.
    Lucente, Vincent
    Forero-Schwanhaeuser, Sergio
    He, Weizhong
    [J]. POSTGRADUATE MEDICINE, 2011, 123 (01) : 94 - 104
  • [32] Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study
    Forester, Brent P.
    Sajatovic, Martha
    Tsai, Joyce
    Pikalov, Andrei
    Cucchiaro, Josephine
    Loebel, Antony
    [J]. AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2018, 26 (02): : 150 - 159
  • [33] Return to Full Baseline Functionality After Repeated Intermittent Use of Midazolam Nasal Spray in Patients With Seizure Clusters: Post-Hoc Analysis of an Open-Label Extension Trial
    Detyniecki, Kamil
    Brunnert, Marcus
    Campos, Rita
    Dimova, Svetlana
    Wheless, James W.
    [J]. NEUROLOGY, 2021, 96 (15)
  • [34] Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study
    Lai, Wyman W.
    Galer, Bradley S.
    Wong, Pierre C.
    Farfel, Gail
    Pringsheim, Milka
    Keane, Martin G.
    Agarwal, Anupam
    [J]. EPILEPSIA, 2020, 61 (11) : 2386 - 2395
  • [35] Evaluating No Evidence of Disease Activity (NEDA) in Patients With Relapsing Multiple Sclerosis: Post Hoc Analysis of the Phase 3 RADIANCE and Open-Label Extension Studies of Ozanimod
    Kappos, L.
    Comi, G.
    Selmaj, K. W.
    Steinman, L.
    Bar-Or, A.
    Arnold, D. L.
    Hartung, H. P.
    Montalban, X.
    Havrdova, E. K.
    Pachai, C.
    Sheffield, J. K.
    Cheng, C. Y.
    Silva, D.
    Vaile, J.
    Morello, J. P.
    Cohen, J. A.
    Cree, B. A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (2_SUPPL) : 11 - 12
  • [36] Open-label extension (OLE) of a multiple ascending dose (MAD) study of BIIB092 in participants with PSP: Safety analysis
    Dam, T.
    Zhang, L.
    Qureshi, I.
    Grundman, M.
    Tirucherai, G.
    Bechtold, C.
    Ahlijanian, M.
    Golbe, L.
    Honig, L.
    Isaacson, S.
    Grossman, M.
    McFarland, N.
    Litvan, I.
    Geldmacher, D.
    Xie, T.
    Bordelon, Y.
    Tuite, P.
    O'Suilleabhain, P.
    Zesiewicz, T.
    Han, B.
    Boxer, A.
    [J]. MOVEMENT DISORDERS, 2018, 33 : S21 - S22
  • [37] Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses
    Armuzzi, Alessandro
    Cross, Raymond K.
    Lichtenstein, Gary R.
    Hou, Jason
    Deepak, Parakkal
    Regueiro, Miguel
    Wolf, Douglas C.
    Akukwe, Lucy
    Ahmad, Harris A.
    Jain, Anjali
    Kozinn, Marc
    Wu, Hsiuanlin
    Petersen, AnnKatrin
    Charles, Lorna
    Long, Millie
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (05)
  • [38] A phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer
    Jones, Robin L.
    Bendell, Johanna C.
    Smith, David C.
    Diefenbach, Konstanze
    Lettieri, John
    Boix, Oliver
    Lockhart, A. Craig
    O'Bryant, Cindy
    Moore, Kathleen N.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 777 - 784
  • [39] A Phase I open-label trial evaluating the cardiovascular safety of regorafenib in patients with advanced cancer
    Jones, R. L.
    Bendell, J. C.
    Smith, D. C.
    Deifenbach, K.
    Lettieri, J.
    Boix, O.
    Lockhart, A. C.
    O'Bryant, C. L.
    Moore, K. N.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S336 - S337
  • [40] A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
    Anthony W. Tolcher
    Leonard J. Appleman
    Geoffrey I. Shapiro
    Alain C. Mita
    Frank Cihon
    Arthur Mazzu
    Pavur R. Sundaresan
    [J]. Cancer Chemotherapy and Pharmacology, 2011, 67 : 751 - 764
12345